You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,163,764


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,163,764
Title:Skincare methods
Abstract: Disclosed are compositions and methods for skincare, e.g., reducing skin wrinkles and for treating skin disorders.
Inventor(s): Chung; Yih-Lin (Taipei, TW), Pui; Nam-Mew (Taipei, TW), Chang; Wei-Wei (Boston, MA)
Assignee: Asan Laboratories Company (Cayman) Limited (Taipei, TW)
Application Number:12/700,843
Patent Claims:1. A method for reducing skin wrinkles comprising administering to a subject in need thereof a composition comprising an effective amount of a histone deacetylase inhibitor or a pharmaceutically acceptable salt thereof, and a cosmetically or pharmaceutically acceptable carrier, wherein the histone deacetylase inhibitor is selected from the group consisting of trichostatin A, trichostatin C, oxamflatin, trapoxin A, FR901228, apicidin, HC-Toxin, WF27082, chlamydocin, salicylihydroxamic acid, suberoylanilide hydroxamic acid, azelaic bishydroxamic acid, azelaic-1-hydroxamate-9-an-ilide, M-carboxycinnamic acid bishydroxamide, 6-(3-chlorophenylureido)carpoic hydroxamic acid, MW2796, MW2996, sodium butyrate, arginine butyrate, isovalerate, valerate, 4-phenylbutyrate, sodium phenylbutyrate, propionate, butrymide, isobutyramide, 3-bromopropionate, valproic acid, valproate, tributyrin, MS-27-275, a 3'-amino derivative, depudecin, and scriptaid.

2. The method of claim 1, wherein the composition is a topical composition and the administering step is conducted by applying the composition to a surface of skin in need thereof of the subject.

3. The method of claim 1, wherein the histone deacetylase inhibitor is trichostatin A or trichostatin C.

4. The method of claim 1, wherein the histone deacetylase inhibitor is selected from the group consisting of oxamflatin, trapoxin A, FR901228, apicidin, HC-Toxin, WF27082, and chlamydocin.

5. The method of claim 1, wherein the histone deacetylase inhibitor is selected from the group consisting of salicylihydroxamic acid, suberoylanilide hydroxamic acid, and azelaic bishydroxamic acid.

6. The method of claim 1, wherein the histone deacetylase inhibitor is selected from the group consisting of azelaic-1-hydroxamate-9-an-ilide, M-carboxycinnamic acid bishydroxamide, 6-(3-chlorophenylureido) carpoic hydroxamic acid, MW2796, and MW2996.

7. The method of claim 1, wherein the histone deacetylase inhibitor is selected from the group consisting of sodium butyrate, arginine butyrate, isovalerate, valerate, 4-phenylbutyrate, sodium phenylbutyrate, propionate, butrymide, isobutyramide, 3-bromopropionate, valproic acid, valproate, and tributyrin.

8. The method of claim 1, wherein the histone deacetylase inhibitor is MS-27-275 or a 3'-amino derivative thereof.

9. The method of claim 1, wherein the histone deacetylase inhibitor is depudecin or scriptaid.

10. The method of claim 1, wherein the histone deacetylase inhibitor is present in an amount of from 0.00001% to 100% by weight of the composition.

11. The method of claim 10, wherein the histone deacetylase inhibitor is present in an amount of from 0.0001% to 10% by weight of the composition.

12. The method of claim 1, wherein the composition is a cream, an ointment, a gel, a paste, a powder, an aqueous solution, a spray, a suspension, a dispersion, a slave, a lotion, a patch, a suppository, a liposome formation, a mouth wash, an enema, an injection solution, an eye drop, an ear drop, a drip infusion, a microcapsule, or a nanocapsule.

13. The method of claim 1, wherein the composition further comprises a penetration enhancing agent, or a pH adjusting agent to provide a formulation pH in the range of approximately 2.0 to 13.0.

14. The method of claim 1, wherein the composition is used as an adjuvant treatment following laser surgery or laser dermabrasion treatment to enhance aged and injured skin rejuvenation.

15. The method of claim 1, wherein the method further comprises administering to the subject a second agent that comprises lidocaine, epinephrine, collagenase, clostridium histolyticum, or combinations thereof.

16. The method of claim 15, wherein the composition and the second agent are systemically or topically administered simultaneously or sequentially.

17. The method of claim 1, wherein the method further comprises, before the administering the composition, identifying a subject having skin wrinkles.

18. The method of claim 1, wherein the method further comprises, after the administering the composition, examining the subject for the effect of the composition on skin wrinkles.

Details for Patent 8,163,764

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Smith & Nephew, Inc. SANTYL collagenase Ointment 101995 06/04/1965 ⤷  Try a Trial 2022-04-26
Auxilium Pharmaceuticals, Inc. XIAFLEX collagenase clostridium histolyticum For Injection 125338 02/02/2010 ⤷  Try a Trial 2022-04-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.